| Name | Title | Contact Details |
|---|
Whitehall Policy Consulting Inc. is a Victoria, BC-based company in the Business Services sector.
Arch Resources is a leading U.S. producer of metallurgical products for the global steel industry, and the leading supplier of premium High-Vol A metallurgical coal globally. Arch and its subsidiaries operate four large, modern metallurgical mines that consistently set the industry standard for both mine safety and environmental stewardship. The flagship Leer mine consistently ranks among the lowest cost U.S. metallurgical mines and produces a product quality that is recognized and sought-after worldwide. An Arch subsidiary is in the process of developing a second world-class longwall mine known as Leer South on the same reserve base. Leer South is expected to commence longwall production in the third quarter of 2021. The startup of Leer South is expected to increase Arch`s annual High-Vol A output to around 8 million tons per year; enhance its already advantageous position on the U.S. cost curve; strengthen its coking coal profit margins across a wide range of market conditions; and solidify its position as the leading supplier of High-Vol A coal globally. The Leer and Leer South operations are complemented by the Beckley and Mountain Laurel mines, which in aggregate provide Arch with a full suite of high-quality metallurgical products for sale into the global metallurgical market. Arch and its subsidiaries also operate highly efficient, low-cost thermal mines in the United States — in the Powder River Basin, Colorado and Illinois. These mines produce highly cost-competitive thermal coal for sale into the domestic and international power generation markets.
Saggezza Inc is a Saint Charles, IL-based company in the Business Services sector.
Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.
Lance Setliff is a Houston, TX-based company in the Business Services sector.